TODAY'S HEADLINES

Opdivo snares another FDA approval

Opdivo (Bristol-Myers Squibb) just received its fifth breakthrough therapy designation in the U.S., but the drug's problems persist in the U.K. Read more

FDA warns about antibacterials

FDA issued a new warning about potentially serious side effects associated with fluoroquinolone antibacterial drugs. Find out which brands and generics are included. Read more

CONTINUING PHARMACY EDUCATION

Keep your patients moving: An overview of treatment options for constipation

This month's CE activity, "Keep your patient moving: An overview of treatment options for constipation," is open for pharmacists and pharmacy technicians.
The goal of this program is to assist pharmacists and pharmacy technicians in their understanding of the role of linaclotide, lubiprostone, methylnaltrexone, and naloxegol in the treatment of constipation after conventional nonpharmacologic interventions and conventional laxatives such as bulking agents, osmotic laxatives, and stimulant laxatives have failed.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

AbbVie to profit from new Viekira Pak uses

FDA recently expanded the use of AbbVie's Viekira Pak to treat patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A). How AbbVie will profit

May 18, 2016

National Managed Care Pharmacy Survey 2016

Your input is needed! Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, is seeking your opinion on the current state of pharmacy. Take the survey and you could win a $200 Visa gift card. Answer Now.

Related Articles

FDA expands Opdivo use for metastatic melanoma

Antipsychotic can cause serious reaction: FDA